1. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis 
Kevin Quach, MSc, Lyubov Lvtvyn, MSc, Colin Baigent, FRCP, Joe Bueti, MD, Amit X. Garg, MD, PhD, Carmel Hawley, MBBS, MMedSci, Richard Haynes, DM, Braden Manns, MD, MSc, Vlado Perkovic, MD, PhD, Christian G. Rabbat, MD, MSc, Ron Wald, MDCM, MPH, Michael Walsh, MD, PhD 
American Journal of Kidney Diseases 
Volume 68, Issue 4, Pages (October 2016)
DOI: /j.ajkd
Copyright © 2016 The Authors Terms and Conditions

2. Figure 1
Flow diagram of search selection. Abbreviation: RCT, randomized controlled trial.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2016 The Authors Terms and Conditions

3. Figure 2
Forest plot of the effects of mineralocorticoid receptor antagonists (MRAs) on cardiovascular mortality in dialysis patients. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2016 The Authors Terms and Conditions

4. Figure 3
Forest plot of the effect of mineralocorticoid receptor antagonists (MRAs) on all-cause mortality in dialysis patients. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2016 The Authors Terms and Conditions

5. Figure 4
Forest plot of the effect of mineralocorticoid receptor antagonists (MRAs) on hyperkalemia in dialysis patients. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2016 The Authors Terms and Conditions